Cancer Patients’ Survival Rates Increase with Use of MGN3

MGN3, a natural immune enhancer marketed by LaneLabs-USA, Inc. (www.lanelabs.com), has increased the lifespan of terminally ill cancer patients by more than 60% according to a recent study. Over 200 patients with a variety of terminal cancers were evaluated for 18 months. Patients given MGN3 plus conventional therapies recorded a 59% survival rate, while those on conventional therapies alone recorded a 33.9% survival rate.

The study, conducted by Dr. Kihachiro Takahara, MD at Japan’s respected Sano Surgical Clinic, was presented at the 3rd Annual Meeting of the Japanese Society of Complementary & Alternative Medicine. The official abstract is available at www.lifeextensionmgn3.com. “This is another example of the dramatic success shown with MGN3,” said Andrew Lane, president of LaneLabs. “We’ve seen MGN3 consistently increase Natural Killer Cell activity as well as B and T cell counts in the body. It also has been shown to reduce the side-effects of radiation and chemotherapy. We hope this new enhanced lifespan data will lead more doctors and patients to seriously explore complementary medicine to combine natural supplements with conventional therapies.” Lane added.

Takahara’s research also found a striking correlation between survival rates and Natural Killer (NK) cell activity, which has been shown in several previous clinical studies to be increased as much as 300% with MGN3 supplementation. In the study, patients whose NK cell activity increased 40% or more during the study recorded a survival rate of 81%.

MGN3, a patented formula of rice bran hydrolyzed with Shiitake mushroom extracts, has been shown in other in vivo/in vitro clinical trials to significantly enhance virtually every critical component of the immune system. It triples NK cell activity, the immune system’s “elite troops” that are the first line of defense against health threats. MGN3 is clinically proven to boost B and T cell activity by 200-250% and heighten cytokine production as well.

MGN3’s research has been presented at renowned medical conferences and published in respected peer-reviewed journals. The long-term efficacy of MGN3 has been clinically proven for a period of five years. Unlike many natural and pharmaceutical biological response modifiers, MGN3 does not cause “hyporesponsiveness,” a brief period of effective immune enhancement followed by a significant drop in immune function despite the continuation of treatment. Many of the clinical trials on MGN3 have been conducted or overseen by Mamdooh Ghoneum, PhD, a UCLA immunologist who pioneered the arabinofuranose compound several decades ago.

For comprehensive research results, go to www.publishedresearch.com.

About LaneLabs
LaneLabs is a leader in innovative, well researched, proprietary natural products for human health. The company dedicates approximately 10% of its revenue annually to the research and development of promising natural therapies. For more information on the LaneLabs family of products, visit them on the web at www.lanelabs.com.